
The Dallas Mavericks’ acquisition of Santi Aldama has been clouded by uncertainty since his arrival, as the forward’s recovery from an undisclosed injury remains vague. Aldama, who played just 43 games last season due to persistent knee issues, underwent an arthroscopic stem cell procedure in March but has yet to show meaningful progress.
He missed both preseason games in Macao, China, and the Mavericks have adopted a cautious approach to his timeline, mirroring their strategy with Dereck Lively II’s recovery. The team traded two future second-round picks and a top-20 protected 2030 first-round pick to Memphis for Aldama, raising questions about whether his long-term availability justifies the investment.
With no clear update on his status, fans and analysts alike are left wondering if Dallas has simply added another high-priced injury risk to its roster—or if Aldama’s shooting and size could still become a valuable asset when he returns.
NBA · 2h ago
NBA · 11h ago
NBA · 11h ago
See all videos